Pirfenidone, a novel anti-fibrotic agent, provides higher benefit for idiopathic pulmonary fibrosis (IPF) patients with better pulmonary function

被引：0
作者：
Ebina, M.
Kimura, Y.
Ohta, H.
Hisata, S.
Tamada, T.
Nukiwa, T.
机构：
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2010年 / 181卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A3988
引用
收藏
页数：1
相关论文
共 50 条
  • [41] CCL 18 as Indicator of Pulmonary Fibrotic Activity in Idiopathic Pulmonary Fibrosis (IPF)
    Lee, R.
    Boylan, D.
    McNicholas, W. T.
    Keane, M. P.
    [J]. IRISH JOURNAL OF MEDICAL SCIENCE, 2012, 181 : S436 - S436
  • [42] Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
    Katrin E Hostettler
    Jun Zhong
    Eleni Papakonstantinou
    George Karakiulakis
    Michael Tamm
    Petra Seidel
    Qingzhu Sun
    Jyotshna Mandal
    Didier Lardinois
    Christopher Lambers
    Michael Roth
    [J]. Respiratory Research, 15
  • [43] Combination of losartan with pirfenidone: a protective anti-fibrotic against pulmonary fibrosis induced by bleomycin in rats
    Amirkhosravi, Arian
    Goki, Maryamossadat Mirtajaddini
    Heidari, Mahmoud Reza
    Karami-Mohajeri, Somayyeh
    Iranpour, Maryam
    Torshabi, Maryam
    Mehrabani, Mitra
    Mandegary, Ali
    Mehrabani, Mehrnaz
    [J]. SCIENTIFIC REPORTS, 2024, 14 (01)
  • [44] PATIENT STORIES: THE USE OF NOVEL ANTI-FIBROTICS, PIRFENIDONE AND NINTEDANIB, IN THE MANAGEMENT OF IDIOPATHIC PULMONARY FIBROSIS, IPF
    Enston-Newall, S.
    [J]. THORAX, 2017, 72 : A247 - A248
  • [45] ADDITION OF PULMONARY REHABILITATION DOES NOT APPEAR TO IMPROVE SIX-MINUTE WALK OR PULMONARY FUNCTION IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS TREATED WITH ANTI-FIBROTIC MEDICATIONS
    Francis, C. E.
    Sylvester, K. P.
    Chiu, Y.
    Thillai, M.
    [J]. THORAX, 2018, 73 : A159 - A160
  • [46] Rate Of Decline In FVC In Non-Ipf Pulmonary Fibrosis After Anti-Fibrotic Initiation
    Brown, J. C.
    Kraft, J.
    Vega-Olivo, M.
    Galli, J.
    Simpson, S.
    Criner, G. J.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [47] IPF Care: A Support Program for Patients with Idiopathic Pulmonary Fibrosis Treated with Pirfenidone in Europe
    Duck, Annette
    Pigram, Lucy
    Errhalt, Peter
    Ahmed, Deeba
    Chaudhuri, Nazia
    [J]. ADVANCES IN THERAPY, 2015, 32 (02) : 87 - 107
  • [48] HEPATIC DISORDERS OF PIRFENIDONE OR NINTEDANIB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) A SYSTEMATIC REVIEW
    Singla, D.
    Mahapatra, S.
    Dey, A.
    John, A.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S218 - S218
  • [49] A Description Of Anti-Fibrotic Therapy Prescribing Preferences Amongst Pulmonary Practitioners For The Management Of Idiopathic Pulmonary Fibrosis
    Jablonski, R.
    Frogameni, A.
    Brown, K. K.
    Kamangar, N.
    Murgu, S.
    Raparia, K.
    Ryu, J.
    Raoof, S.
    Suh, R. D.
    Edell, E. S.
    Kamp, D. W.
    Raj, R.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [50] The long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF)
    Valeyre, Dominique
    Albera, Carlo
    Bradford, Williamson
    Costabel, Ulrich
    King, Talmadge
    Noble, Paul
    Sahn, Steven
    du Bois, Roland
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2012, 40
12345